These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 36249023)

  • 21. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
    Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
    Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.
    Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ
    Front Oncol; 2022; 12():954203. PubMed ID: 36505818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
    Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
    Front Oncol; 2022; 12():950266. PubMed ID: 35860582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study.
    Yang B; Jie L; Yang T; Chen M; Gao Y; Zhang T; Zhang Y; Wu H; Liao Z
    Front Oncol; 2021; 11():821599. PubMed ID: 35004336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P; Pi X; Gao F; Li Q; Li D; Feng W; Cao W
    Front Oncol; 2022; 12():945915. PubMed ID: 36338683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Jiang J; Zhang H; Lai J; Zhang S; Ou Y; Fu Y; Zhang L
    J Hepatocell Carcinoma; 2024; 11():1607-1622. PubMed ID: 39206422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
    Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
    Ma KP; Fu JX; Duan F; Wang MQ
    World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study.
    Lu H; Zheng C; Liang B; Xia X; Fan H
    Front Oncol; 2024; 14():1280837. PubMed ID: 38298738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Yang H; Yang T; Qiu G; Liu J
    J Hepatocell Carcinoma; 2023; 10():1435-1443. PubMed ID: 37691972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Wang L; Lin L; Zhou W
    Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G; Yin L; Liu R; Cui Y
    Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.